Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465709 · ClinicalTrials.gov registry record · Phase 1
Pegcetacoplan (APL-2) in Neovascular AMD
A Phase 1 study, sponsored by Apellis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03465709 is a Phase 1 study that was terminated before completion, run by Apellis Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT03465709, a Phase 1 study, was terminated before completion, sponsored by Apellis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
Interventions
- DRUG Pegcetacoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03465709
The ClinicalTrials.gov registry entry for NCT03465709 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT03465709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03465709 about?
NCT03465709 is a clinical study titled "Pegcetacoplan (APL-2) in Neovascular AMD". Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
What is the current status of trial NCT03465709?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-02-14. Estimated completion is 2019-04-05.
What interventions are being tested in trial NCT03465709?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT03465709?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.